Lasting pathologic complete response to chemotherapy for ovarian cancer after receiving antimalarials for dermatomyositis
Isabella Cadena(New York University), Franco M. Muggia(NYU Langone Health), Annie Yang(Molecular Oncology (United States)), Victoria P. Werth(Philadelphia VA Medical Center), Andrea Downey(University of New Mexico), John P. Curtin(Cork University Hospital), Pascale Levine(University of Massachusetts Chan Medical School)
Cited by 9
Related Papers
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
|Journal of the American Academy of Dermatology|2008|597
Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts
|Journal of the American Academy of Dermatology|2011|379
239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018
|Neuromuscular Disorders|2019|308
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Reliability and Convergent Validity of Two Outcome Instruments for Pemphigus
|Journal of Investigative Dermatology|2009|238